The BioMed X Institute
19.12.2023 10:03:15 CET | ACCESS Newswire | Press release
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan. The project entitled "New Strategies to Engage Neutrophils in Solid Tumors" will be hosted by the BioMed X Institute in Heidelberg, Germany. The goal of this research project is to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.
Developing immunotherapies that target T cells has proved highly effective, and it is still a rapidly evolving research area. However, many patients remain resistant to these therapies, necessitating the development of novel immunological strategies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems to be paradoxical according to the data accumulated thus far. By uncovering novel neutrophil biology, this project aims to leverage their functions to design novel immunotherapies.
The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C03 before February 18, 2024.
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Oncology and immunology, including tumor immunology, are key areas of expertise at BioMed X. We are proud and honored that Ono has chosen our institute to develop new strategies for engaging neutrophils in cancer therapy".
Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono Pharmaceutical: "We are very pleased to form a partnership with BioMed X in our mission dedicated to overcoming cancer. This innovative research collaboration will engage us with highly talented scientists around the world who possess unique ideas for immunotherapy utilizing neutrophils. We believe that the research team established through this collaboration will lead to the discovery of the next generation of immunotherapy with us".
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
About Ono
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/en.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
View the original press release on newswire.com.
SOURCE: BioMed X Institute
To view this piece of content from stats.newswire.com, please give your consent at the top of this page. To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
The Numbers are Clear: Latest Iteration of Stagwell's News Advertising Study Shows Germans Love Their News18.2.2026 11:00:00 CET | Press release
Stagwell, Axel Springer, Teads and The Trade Desk partner on German News Advertising Study, drawing insights from over 11,000 respondents Study finds the proportion of ‘news junkies' in Germany is highest of all the surveyed markets BERLIN, GERMANY / ACCESS Newswire / February 18, 2026 / Stagwell, the global challenger network transforming marketing through AI, released the latest installment of its News Advertising Study in partnership with Axel Springer, Teads and The Trade Desk. The survey, fielded among 11,282 adults in Germany, builds on Stagwell's prior News Advertising studies conducted in Asia Pacific, Canada, the U.S. and UK. This regional study further reinforces it is safe for brands to advertise adjacent to quality news content agnostic of the topic. "The Future of News research for the German market illustrates how important it is for brands to advertise in quality news publications. Germany has a 10-percentage point higher share of news enthusiasts than other markets, and
Kraft Heinz, Braskem, and Tenaris to headline OMP Conference São Paulo 202617.2.2026 15:00:00 CET | Press release
Global industry leaders showcase real-world results and AI-driven supply chain planning innovations SÃO PAULO, BR / ACCESS Newswire / February 17, 2026 / OMP, a leading provider of AI-powered supply chain planning solutions, brings its REAL conference series to Latin America with a one-day event in São Paulo on April 16, 2026. The conference will bring together Fortune 500 leaders to share how they are transforming global operations through digital innovation. Under the theme "Real expertise. Real solutions. Real results," the conference focuses on the practical application of AI in complex supply chain environments. The agenda is anchored by three global powerhouses who will provide a "behind-the-scenes" look at their digital transformation journeys in partnership with OMP's Unison Planning™: Kraft Heinz, a global food and beverage company, will demonstrate how data-driven planning, AI-enabled optimization, and end-to-end visibility are building a more agile and sustainable value chai
Supported by U.S. Polo Assn., the 2026 U.S. Open Women's Polo Championship(R) Concludes with Victory Eastern Hay the Champion17.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL / ACCESS Newswire / February 17, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the 2026 U.S. Open Women's Polo Championship®, which concluded on February 15 at the USPA National Polo Center (NPC) in Wellington, Florida, on the iconic U.S. Polo Assn. Stadium Field. Widely regarded as the most prestigious women's polo tournament in the United States, the championship brought together the sport's top athletes for three weeks of elite competition at the heart of American polo.1. Victory Eastern Hay proudly displaying their trophy as winner of the 2026 U.S. Open Women's Polo Championship at the USPA National Polo Center 2. Victory Eastern Hay Team on horseback (#1 Rebecca Schmeits, #2 Aspen Tinto, #3 Hazel Jackson, #4 Milly Hine) at the 2026 U.S. Open Women's Polo Championship 3. La Dolfina Team presents a donation to their charity of choice, Polo Players Support Group, provided by U.S. Polo Assn., at th
Camino Intercepts High-Grade Copper with 83.5m at 0.94% Cu including 7.1m at 2.13% Cu at Los Chapitos, Peru17.2.2026 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company")is pleased to announce the exploration results from Phase 1 of the recent drilling campaign at its Los Chapitos copper project ("Los Chapitos" or the "Project") in Peru. This news release reports the results from eight drill holes completed along the Diva trend corridor, where drilling activities focused on several targets with the objective of expanding the known mineralized body and improving the understanding of the scale and continuity of the mineralized system. Los Chapitos is Camino's second copper project with partner Nittetsu Mining Co, Ltd. ("Nittetsu"), who is completing a 35% earn-in interest in Los Chapitos after investing CAD $10 million and after the completion of Phase 2 of the current drilling campaign (see news release dated June 14, 2023). Camino is also advancing its Puquios Copper Project in Chile with Nittetsu Mining towards mine cons
Datavault AI Updates Revenue Estimates by Approximately 30% at $38M to $40M17.2.2026 12:00:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / February 17, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today announced its updated preliminary (unaudited) fiscal year 2025 revenue is estimated to be $38 to $40 million, exceeding its prior estimate of $30 million by up to 33%. At its midpoint, estimated FY-25 revenue represents approximately 1,300% growth year-over-year The Company attributed this revenue growth to its customer tech-licensing fees, and its Data Science Group's tokenization and monetization services. Further, Datavault AI reaffirmed its anticipated FY-26 revenue of $200 million, which, if achieved, would represent a year-over-year increase of 400% to 440%. KEY FINANCIAL METRICS FY 2025 (Preliminary, Unaudited): Estimated Revenue: $38-$40 million Prior Estimate: $30 million Incremental Change: +$8-$10 million (+27% to +33%) Midpoint:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom